Categories: All CategoriesCorporateProductsPipelineFinancial Sep 13, 2021Myriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorpCorporateSep 08, 2021Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide surveyProductsAug 03, 2021Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation PlansFinancialAug 02, 2021Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All AncestriesPipelineJul 28, 2021Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021FinancialJul 28, 2021New research reveals most Americans can’t identify the symptoms of depressionProductsJul 21, 2021Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All EthnicitiesCorporateJul 01, 2021Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 SolutionsCorporateJun 16, 2021Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad GeneticsCorporateJun 04, 2021Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare ConferenceCorporateJun 01, 2021Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle BiosciencesCorporateMay 24, 2021Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 SolutionsCorporateMay 20, 2021 Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health BusinessCorporateMay 19, 2021Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All AncestriesPipelineMay 05, 2021Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care ConferenceCorporate Next page
